News & Updates

Twelve weeks of treatment with the aldosterone synthase inhibitor lorundrostat proved efficacious and safe for lowering blood pressure (BP) in adults with uncontrolled hypertension, including those who were resistant to treatment, according to the phase III Launch-HTN trial.

Deucravacitinib exhibits superiority over placebo in terms of overall disease activity measures, musculoskeletal and dermatologic manifestations, and quality of life in adults with active psoriatic arthritis (PsA) who are naïve to biologic disease-modifying antirheumatic drugs (DMARDs), according to the results of the POETYK PsA-1 study.

Depression and the use of SSRIs appear to significantly contribute to an individual’s sexual functioning, distress, and pleasure, according to a study.

Long-term treatment with delgocitinib is well-tolerated and raises no major safety concerns among patients with chronic hand eczema (CHE), results of the DELTA 3 trial have shown. Its use also maintains disease control for up to 52 weeks.